Literature DB >> 8682116

Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.

H J Dargie1, I Ford, K M Fox.   

Abstract

OBJECTIVE: To study the relationship between presence or absence of ischaemic events on Holter monitoring and occurrence of a hard or hard+soft endpoint.
DESIGN: A randomized double-blind parallel group study of atenolol, nifedipine and their combination, with ambulatory monitoring off-treatment and after 6 weeks of randomized treatment and prospective follow-up of 2 years on average.
SETTING: Europe.
SUBJECTS: 682 men and women with a diagnosis of chronic stable angina and who were not being considered for surgery. MAIN OUTCOME: Hard endpoints were cardiac death, nonfatal myocardial infarction and unstable angina; soft endpoints were coronary artery bypass surgery, coronary angioplasty and treatment failure.
RESULTS: The study showed no evidence of an association between the presence, frequency or total duration of ischaemic events on Holter monitoring, either on or off treatment, and the main outcome measures. There was a non-significant trend to a lower rate of hard endpoints in the group receiving combination therapy. Compliance, as measured by withdrawal from trial medication, was clearly poorest in the nifedipine group with similar withdrawal rates in the atenolol and combination therapy groups.
CONCLUSION: The recording of ischaemic events in 48 h Holter monitoring failed to predict hard or hard+soft endpoints in patients with chronic stable angina.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8682116     DOI: 10.1093/oxfordjournals.eurheartj.a014668

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  31 in total

1.  Investigation and management of stable angina: revised guidelines 1998. Joint Working Party of the British Cardiac Society and Royal College of Physicians of London.

Authors:  D de Bono
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

2.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

3.  Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.

Authors: 
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 4.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 5.  ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques.

Authors:  Peter H Stone
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-04       Impact factor: 1.468

6.  The return of silent ischaemia? Not really.

Authors:  D A Mulcahy
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

Review 7.  Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review.

Authors:  C Michael Gibson; Lauren N Ciaglo; Matthew C Southard; Shaun Takao; Caitlin Harrigan; Jason Lewis; Jason Filopei; Michelle Lew; Sabina A Murphy; Jacqueline Buros
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

Review 8.  Antianginal actions of beta-adrenoceptor antagonists.

Authors:  Stephen T O'Rourke
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

Review 9.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

Review 10.  [Long term electrocardiography (Holter monitoring)].

Authors:  Axel Brandes; Klaus-Peter Bethge
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.